Drug Trial Radar · NCT07843940
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Apr 17, 2030
Study completion Apr 21, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
Conditions
- Extensive-stage Small Cell Lung Carcinoma
- Advanced Small Cell Lung Cancer
Interventions
ObrixtamigDrug
Obrixtamig
PumitamigDrug
Pumitamig
CarboplatinDrug
Carboplatin
EtoposideDrug
Etoposide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modificationTime frame: up to 27 months
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
New York University Langone Medical Center
New York, New York · Not yet recruiting
SCRI Oncology Partners
Nashville, Tennessee · Not yet recruiting
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia · Not yet recruiting
Townsville University Hospital
Douglas, Queensland, Australia · Not yet recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Not yet recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, China · Not yet recruiting
CTR Leon Berard
Lyon, France · Not yet recruiting
HOP Timone
Marseille, France · Not yet recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Technische Universität Dresden
Dresden, Germany · Not yet recruiting
Universitätsklinikum Essen AöR
Essen, Germany · Not yet recruiting
Universitätsklinikum Tübingen
Tübingen, Germany · Not yet recruiting
Okayama University Hospital
Okayama, Okayama, Japan · Not yet recruiting
Kansai Medical University Hospital
Osaka, Hirakata, Japan · Not yet recruiting
Shizuoka Cancer Center
Shizuoka, Sunto-gun, Japan · Not yet recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Not yet recruiting
Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Brzozów, Poland · Not yet recruiting
Lower Silesian Oncology Centre
Wroclaw, Poland · Not yet recruiting
Hospital Clínic de Barcelona
Barcelona, Spain · Not yet recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Not yet recruiting
Hospital Clinico De Valencia (INCLIVA)
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.